TrialJournal of hematology & oncology2014

Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.

Vivek Subbiah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.